
Opinion|Videos|August 23, 2024
Management of Comment Adverse Effects Associated with mCRPC Therapies
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.
Advertisement
Episodes in this series

How do you manage common side effects associated with mCRPC treatments, including androgen receptor-targeted therapies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH
2
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
3
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
4
Contextualizing Cretostimogene in the Evolving Treatment Landscape
5








